⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1627415 | 0.86 | CA1 (0.32) | — | |
| SCHEMBL12444789 | 0.86 | CA1 (0.38) | — | |
| SCHEMBL14346326 | 0.79 | ABCB1 (0.37) | — | |
| SCHEMBL431589 | 0.77 | — | — | |
| SCHEMBL11921322 | 0.73 | SLC6A1 (0.30) | — | |
| SCHEMBL19654731 | 0.72 | — | — | |
| SCHEMBL8898871 | 0.70 | TRIM24 (0.38) | — | |
| SCHEMBL16622400 | 0.69 | — | — | |
| SCHEMBL6673136 | 0.69 | CA1 (0.35) | — | |
| SCHEMBL28961100 | 0.69 | CA1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9246187-B2 | Non-aqueous electrolyte for lithium-ion battery | UCHICAGO ARGONNE, LLC (US) | 2016-01-26 | — | — | US | disclosed |
| US-9218915-B2 | Non-aqueous electrolyte for lithium-ion battery | UCHICAGO ARGONNE, LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140272607-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM-ION BATTERY | UCHICAGO ARGONNE LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140186721-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM-ION BATTERY | UCHICAGO ARGONNE, LLC (US) | 2014-07-03 | — | — | US | disclosed |
| US-20120088160-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM-ION BATTERY | UCHICAGO ARGONNE, LLC | 2012-04-12 | — | — | US | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| EP-2178874-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |